Journal
ANTI-CANCER DRUGS
Volume 21, Issue 4, Pages 339-350Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e3283350dd1
Keywords
AT9283; aurora kinase inhibitors; AZD1152; ENMD-2076; MLN8237; PF03814735; PHA739358; SNS-314; VX680/MK0457; VX689/MK5108
Categories
Ask authors/readers for more resources
Aurora kinases are serine and threonine kinases that function as key regulators of the mitosis process. There are three distint human aurora kinases known as Aurora A, Aurora B, and Aurora C. Aurora A and Aurora B are overexpressed in a number of human cancers including non-small cell lung cancer, glioblastomas, and upper gastrointestinal adenocarcinomas. Given their association with tumorigenesis, both Aurora A and Aurora B have been targeted for cancer therapy. Currently, a number of selective and nonselective aurora kinase inhibitors are being tested in preclinical and clinical settings as anti-tumor agents. We review the biology of human aurora kinases, followed by an overview of inhibitors undergoing current clinical investigations. Anti-Cancer Drugs 21: 339-350 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available